Today established as the worldwide leader for salicylic acid, Novacap [1] has also an excellent position in other essential ingredients, such as methyl salicylate and sodium bicarbonate. The company now intends to leverage on its global leadership positions in pharmaceuticals to conquer the cosmetic market.
M&A strategy
For the last three years, Novacap has significantly broaden its cosmetic portfolio via several key acquisitions: Uetikon, in 2015, a German company specializing in tailor made synthesis of complex molecules for pharmaceutical and cosmetic industries, Chemoxy in 2017, a British company, specialized in custom processing, solvent recovery, environmentally friendly solvents, and specialty personal care ingredients such as emollient, preservative booster esters, and in 2017 too, ID bio, a French company specialized in classical or biotechnological extraction and purification of botanical substances, and PCAS, a company specializing in the development and manufacturing of complex molecules for life science industries.
This dynamic mergers and acquisitions strategy, completed by the group’s initial know-how in pharmaceutics and fine chemistry, now allows Novacap to offer a cutting-edge portfolio for the cosmetic market.
|
A comprehensive cosmetic offer |
Blockchain technology
In line with its strong ambition, Novacap has chosen to invest in the blockchain technology, which will be deployed first in the group’s botanical and biotech active business units by the end of 2018.
“The first ambition is to guaranty the traceability of organic active ingredients, in compliance with Ecocert/Cosmos label, from raw material purchase to finished product shipment,” the company highlights.
